DEC 2 2 20001

TECH CENTER 1600/2900

```
TRADEMARK.
                                SEQUENCE LISTING
<110> Parham, Christi L.
      Moore, Kevin W.
      Murgolo, Nicholas J.
      Bazan, J. Fernando
<120> Human Receptor Proteins; Related Reagents and Methods
<130> DX0804K
<140> 09/265,540
<141> 1999-03-08
≮160> 6
<170> PatentIn Ver. 2.0
<210> 1
<211> 1381
<212> DNA
<213> primate
<220>
<221> CDS
<222> (132)..(1064)
<220>
<221> misc feature
<222> (567)
<223> n at position 567; n may be A\lambda C, G, or T;
      translated amino acid depends on genetic code
```

<220>

<221> misc feature

<222> (573)

<223> n at position 573; n may be A, C, G, or T; translated amino acid depends on genetic code

<220> <221> misc feature

<222> (1336)

<223> n at position 1336; n may be A,C, G,\or T; translated amino acid depends on genetic code

<220>

<221> misc feature

<222> (1342)

<223> n at position 1342; n may be A, C, G, or T; translated amino acid depends on genetic\code

<220>

<221> misc feature

<222> (1369)

<223> n at position 1369; n may be A, C, G, or T; translated amino acid depends on genetic code

<400> 1 tcgacccacg cgtccgcgct gcgactcaga cctcagctcc aacatatgca ttctgaagaa 60 agatggctga gatggacaga atgctttatt ttggaaagaa acaatgttct aggtcaaact 120 gagtctacca a atg cag\act ttc aca atg gtt cta gaa gaa atc tgg aca Met Gln Thr Phe Thr Met Val Leu Glu Glu Ile Trp Thr agt ctt ttc atg tgg ttt ttc tac gca ttg att cca tgt ttg ctc aca Ser Leu Phe Met Trp Phe Phe Tyr Ala Leu Ile Pro Cys Leu Leu Thr gat gaa gtg gcc att ctg cct gcc cct cag aac ctc tct gta ctc tca Asp Glu Val Ala Ile Leu Pro Ala Pro Gln Asn Leu Ser Val Leu Ser acc aac atg aag cat ctc ttog atg tgg agc cca gtg atc gcg cct gga Thr Asn Met Lys His Leu Leu Met Trp Ser Pro Val Ile Ala Pro Gly qaa aca gtg tac tat tct gtc gaa tac cag ggg gag tac gag agc ctg Glu Thr Val Tyr Tyr Ser Val 🞝 u Tyr Gln Gly Glu Tyr Glu Ser Leu tac acg age cae ate tgg ate ced age age tgg tge tea ete act gaa Tyr Thr Ser His Ile Trp Ile Pro\Ser Ser Trp Cys Ser Leu Thr Glu ggt cct gag tgt gat gtc act gat gac atc acg gcc act gtg cca tac Pro Glu Cys Asp Val Thr Asp Asp Ile Thr Ala Thr Val Pro Tyr aac ctt cgt gtc agg gcc aca ttg ggc \tca cag acc tca gcc tgg agc Asn Leu Arg Val Arg Ala Thr Leu Gly Ser Gln Thr Ser Ala Trp Ser atc ctg aag cat ccc ttt aat aga aac tda acc atc ctt acc cga cct Ile Leu Lys His Pro Phe Asn Arg Asn Set Thr Ile Leu Thr Arg Pro ggg atg gag atc ncc aaa nat ggc ttc cac ttg gtt att gag ctg gag Gly Met Glu Ile Xaa Lys Xaa Gly Phe His Leu Val Ile Glu Leu Glu gac ctg ggg ccc cag ttt gag ttc ctt gtg gck tac tgg asg agg gag Asp Leu Gly Pro Gln Phe Glu Phe Leu Val Ala Tyr Trp Xaa Arg Glu cct ggt gcc gag gaa cat gtc aaa atg gtg agg aggt ggt att cca Pro Gly Ala Glu Glu His Val Lys Met Val Arg Ser Gly Gly Ile Pro 18\5 gtg cac cta gaa acc atg gag cca ggg gct gca tac tgt gtg aag gcc Val His Leu Glu Thr Met Glu Pro Gly Ala Ala Tyr Cys Val Lys Ala

July 1

•	
cag aca ttc gtg aag gcc att ggg arg tac agc gcc ttc agc cag aca Gln Thr Phe Val Lys Ala Ile Gly Xaa Tyr Ser Ala Phe Ser Gln Thr 210 215 220	794
gaa tgt gtg gar gtg caa gga gag gcc att ccc ctg gta ctg gcc ctg Glu Cys Val Xaa Val Gln Gly Glu Ala Ile Pro Leu Val Leu Ala Leu 225 230 235	842
ttt gcc ttt gtt ggc ttd atg ctg atc ctt gtg gtc gtg cca ctg ttc Phe Ala Phe Val Gly Phe Met Leu Ile Leu Val Val Val Pro Leu Phe 240 245 250	890
gtc tgg aaa atg ggc cgg ctg ctc cag tac tcc tgt tgc ccc gtg gtg Val Trp Lys Met Gly Arg Leu Leu Gln Tyr Ser Cys Cys Pro Val Val 255 260 265	938
gtc ctc cca gac acc ttg aaa ata acc aat tca ccc cag aag tta atc Val Leu Pro Asp Thr Leu Lys Ile Thr Asn Ser Pro Gln Lys Leu Ile 270 275 280 285	986
agc tgc aga agg gag gtg gat gcc tgt gcc acg gct gtg atg tct Ser Cys Arg Arg Glu Glu Val Asp Ala Cys Ala Thr Ala Val Met Ser 290 295 300	1034
cct gag gaa ctc ctc agg gcc tgg atc tca taggtttgcg gaagggccca Pro Glu Glu Leu Arg Ala Tro Ile Ser 305 310	1084
ggtgaagccg agaacctggt ctgcatgaca tggaaaccat gaggggacaa gttgtgttt	c 1144
tgttttccgc cacggacaag ggatgagaga agtaggaaga gcctgttgtc tacaagtct	a 1204
gaagcaacca tcagaggcag ggtggtttgt ckaacagaac aaytgactga ggytakrgg	ıg 1264
gwtgtgacct ctagactktg ggstkscayt dgcwtggytg agcaaccctg ggaaaagtg	ya 1324
cttcatccct tnggtccnaa gttttctcat ctgtaatggg ggatncctac aaaactg	1381
<pre> <210> 2 <211> 311 <212> PRT <213> primate </pre>	
<pre><400> 2 Met Gln Thr Phe Thr Met Val Leu Glu Glu Ile Trp Thr Ser Leu Phe</pre>	
Met Trp Phe Phe Tyr Ala Leu Ile Pro Cys Leu Leu Thr Asp Glu Val 20 25 30	
Ala Ile Leu Pro Ala Pro Gln Asn Leu Ser Val Leu Ser Thr Asn Met 35 40 45	
Lys His Leu Leu Met Trp Ser Pro Val Ile Ala Pro Gly Glu Thr Val	

The state of the s

Tyr Tyr Ser Val Glu Tyr Gln Gly Glu Tyr Glu Ser Leu Tyr Thr Ser His Ile Trp Ile Pro Ser Ser Trp Cys Ser Leu Thr Glu Gly Pro Glu Cys Asp Val Thr Asp Asp Ile Thr Ala Thr Val Pro Tyr Asn Leu Arg Val Arg Ala Thr Leu\Gly Ser Gln Thr Ser Ala Trp Ser Ile Leu Lys His Pro Phe Asn Arg Asn Ser Thr Ile Leu Thr Arg Pro Gly Met Glu Ile Xaa Lys Xaa Gly Phe His Leu Val Ile Glu Leu Glu Asp Leu Gly Pro Gln Phe Glu Phe Leu\Val Ala Tyr Trp Xaa Arg Glu Pro Gly Ala Glu Glu His Val Lys Met Val Arg Ser Gly Gly Ile Pro Val His Leu Glu Thr Met Glu Pro Gly Ala Ala Tyr Cys Val Lys Ala Gln Thr Phe Val Lys Ala Ile Gly Xaa Tyr Ser Ala Phe Ser Gln Thr Glu Cys Val Xaa Val Gln Gly Glu Ala Ile Pro Leu Val Leu Ala Leu Phe Ala Phe Val Gly Phe Met Leu Ile Leu Val Val Val Pro Leu Phe Val Trp Lys Met Gly Arg Leu Leu Gln Tyr Ser\ Cys Cys Pro Val Val Leu Pro Asp Thr Leu Lys Ile Thr Asn Ser Aro Gln Lys Leu Ile Ser Cys Arg Arg Glu Glu Val Asp Ala Cys Ala Thr Ala Val Met Ser Pro Glu Glu Leu Leu Arg Ala Trp Ile Ser <210> 3 <211> 1244 <212> DNA <213> primate <220> <221> CDS <222> (2)..(694)

. . .

<400> 3 c cgg gtc gac ccalcgc gtc cgc ctg gtt tcc ccc tgg ctg aca gtg cct 49 Arg Val Asp Pro Arg Val Arg Leu Val Ser Pro Trp Leu Thr Val Pro tgg ttc ctg tcc tgt\tgg aat gtt acc att ggg cct cct gag agc atc Trp Phe Leu Ser Cys \Trp Asn Val Thr Ile Gly Pro Pro Glu Ser Ile tgg gtg acg ccg gga ga gcc tcc ctc atc atc agg ttc tcc tct ccc Trp Val Thr Pro Gly Gl& Ala Ser Leu Ile Ile Arg Phe Ser Ser Pro ttc gac gtc cct ccc aac ctg ggc tat ttc cag tac tat gtc cat tay Phe Asp Val Pro Pro Asn Deu Gly Tyr Phe Gln Tyr Tyr Val His Xaa tgg gaa aag gcg gga atc caa aag gtt aaa ggt cct ttc aag agc aac Trp Glu Lys Ala Gly Ile Gln\Lys Val Lys Gly Pro Phe Lys Ser Asn tcc atc gtg ttg gat ggc ttg aga ccc tta aga gaa tac tgt tta caa Ser Ile Val Leu Asp Gly Leu Arg Pro Leu Arg Glu Tyr Cys Leu Gln gtg aag gcg cat ctc ttt cgc aca \tcc tgc aac acc tct agg ccc ggc Val Lys Ala His Leu Phe Arg Thr Ser Cys Asn Thr Ser Arg Pro Gly cgc tta agc aac ata act tgc tac gaa aca atg atg gat gcc act acg Arg Leu Ser Asn Ile Thr Cys Tyr Glu\ Thr Met Met Asp Ala Thr Thr aag ctt caa caa gtc atc ctc atc gcc gtg gga gtc ttt ctg tcg ctg Lys Leu Gln Gln Val Ile Leu Ile Ala Val Gly Val Phe Leu Ser Leu gcg gcg ctg gcg ggc tgt ttc ttc ctg\gtg ctg aga tac aaa ggc Ala Ala Leu Ala Gly Gly Cys Phe Phe Leu Val Leu Arg Tyr Lys Gly ctg gtg aaa tac tgg ttt cac tct ccg cca agc atc cca tca caa atc Leu Val Lys Tyr Trp Phe His Ser Pro Pro Set Ile Pro Ser Gln Ile gaa gag tat ctg aag gac ccg agc cag cct atc ta gag gcc ctg gac Glu Glu Tyr Leu Lys Asp Pro Ser Gln Pro Ile Leu Glu Ala Leu Asp aag gac acg tca cca aca gat gat gcc tgg gac ttg gtg tct gtt gtt Lys Asp Thr Ser Pro Thr Asp Asp Ala Trp Asp Leu Val Ser Val Val 05 gca ttt cca gca aag gag caa gaa gat gtt ccc caa agc act ttg acc Ala Phe Pro Ala Lys Glu Gln Glu Asp Val Pro Gln Set Thr Leu Thr

MB WANT

caa aac tct ggt gcg gtc tgc tagcctgtgg ggtaagggct ctgagccgag 724 Gln Asn Ser Gly Ala Val Cys 280

<210> 4 <211> 231 <212> PRT <213> primate

<400> 4

Arg Val Asp Pro Arg Val Arg Leu Val Ser Pro Trp Leu Thr Val Pro
1 10 15

Trp Phe Leu Ser Cys Trp Asn Val Thr Ile Gly Pro Pro Glu Ser Ile
20 30

Trp Val Thr Pro Gly Glu Ala Ser Leu Ile Ile Arg Phe Ser Ser Pro
35 40 45

Phe Asp Val Pro Pro Asn Leu Gly Tyr Phe Gln Tyr Tyr Val His Xaa 50 55 60

Trp Glu Lys Ala Gly Ile Gln Lys Val Lys Gly Pro Phe Lys Ser Asn 65 70 75 80

Ser Ile Val Leu Asp Gly Leu Arg Pro Leu Arg Glu Tyr Cys Leu Gln
85 90 95

Val Lys Ala His Leu Phe Arg Thr Ser Cys Asn Thr Ser Arg Pro Gly
100 105 110

Arg Leu Ser Asn Ile Thr Cys Tyr Glu Thr Met Met Asp Ala Thr Thr 115 120 125

Lys Leu Gln Gln Val Ile Leu Ile Ala Val Gly Val Phe Leu Ser Leu 130 135

ABOUT CORNER

3

Ala Ala Leu Ala Gly Gly Cys Phe Phe Leu Val Leu Arg Tyr Lys Gly
145 155 160

Leu Val Lys Tyr Trp Phe His Ser Pro Pro Ser Ile Pro Ser Gln Ile 165 170 175

Glu Glu Tyr Leu Lys Asp Pro Ser Gln Pro Ile Leu Glu Ala Leu Asp 180 185 190

Lys Asp Thr Ser Pro Thr Asp Asp Ala Trp Asp Leu Val Ser Val Val
195 200 205

Ala Phe Pro Ala Lys Glu Gln Glu Asp Val Pro Gln Ser Thr Leu Thr 210 220

Gln Asn Ser Gly Ala Val Cys 225 230

<210> 5

<211> 337

<212> PRT

<213> primate

<400> 5

Met Arg Pro Thr Leu Leu Trp Ser Leu Leu Leu Leu Leu Gly Val Phe 1 5 10

Ala Ala Ala Ala Ala Pro Pro Asp Pro Leu Ser Gln Leu Pro Ala 20 30

Pro Gln His Pro Lys Ile Arg Leu Tyr Asn Ala Glu Gln Val Leu Ser
35 40 45

Trp Glu Pro Val Ala Leu Ser Asn Ser Thr Arg Pro Val Val Tyr Arg
50 60

Val Gln Phe Lys Tyr Thr Asp Ser Lys Trp Phe Thr Ala Asp Ile Met
65 75 80

Ser Ile Gly Val Asn Cys Thr Gln Ile Thr Ala Thr Glu Cys Asp Phe
85 90 95

Thr Ala Ala Ser Pro Ser Ala Gly Phe Pro Met Asp Phe Asn Val Thr
100 105 110

Leu Arg Leu Arg Ala Glu Leu Gly Ala Leu His Ser Ala Trp Val Thr
115 120 125

Met Pro Trp Phe Gln His Tyr Arg Asn Val Thr Val Gly Pro Pro Glu
130 135 140

Asn Ile Glu Val Thr Pro Gly Glu Gly Ser Let Ile Ile Arg Phe Ser 145 150 150

Ser Pro Phe Asp Ile Ala Asp Thr Ser Thr Ala Phe Phe Cys Tyr Tyr
165 170 175

The state of the s

Val His Tyr Trp Glu Lys Gly Gly Ile Gln Gln Val Lys Gly Pro Phe Arg Ser Asn Ser Ile Ser Leu Asp Asn Leu Lys Pro Ser Arg Val Tyr Cys Leu Gln Val Gln Ala Gln Leu Leu Trp Asn Lys Ser Asn Ile Phe Arg Val Gly His Leu Ser\Asn Ile Ser Cys Tyr Glu Thr Met Ala Asp Ala Ser Thr Glu Leu Gln Gln Val Ile Leu Ile Ser Val Gly Thr Phe Ser Leu Leu Ser Val Leu Ala Gly Ala Cys Phe Phe Leu Val Leu Lys Tyr Arg Gly Leu Ile Lys Tyr Trp Phe His Thr Pro Pro Ser Ile Pro Leu Gln Ile Glu Glu Tyr Leu Lys Asp Pro Thr Gln Pro Ile Leu Glu Ala Leu Asp Lys Asp Ser Ser Pro Lys Asp Asp Val Trp Asp Ser Val Ser Ile Ile Ser Phe Pro Glu Lys\Glu Glu Glu Asp Val Leu Gln Thr

Leu

<210> 6

<211> 325

<212> PRT

<213> primate

<400> 6

Met Ala Trp Ser Leu Gly Ser Trp Leu Gly Gly Cys Leu Leu Val Ser

Ala Leu Gly Met Val Pro Pro Pro Glu Ash Val Arg Met Asn Ser Val

Asn Phe Lys Asn Ile Leu Gln Trp Glu Ser \Pro Ala Phe Ala Lys Gly

Asn Leu Thr Phe Thr Ala Gln Tyr Leu Ser Tyr Arg Ile Phe Gln Asp

Lys Cys Met Asn Thr Thr Leu Thr Glu Cys Asp Phe Ser Ser Leu Ser

Lys Tyr Gly Asp His Thr Leu Arg Val Arg Ala Glu Phe Ala Asp Glu

His Ser Asp Trp Val Asn Ile Thr Phe Cys Pro Val Asp Asp Thr Ile Ile Gly Pro Pro G1/y Met Gln Val Glu Val Leu Ala Asp Ser Leu His Met Arg Phe Leu Ala\Pro Lys Ile Glu Asn Glu Tyr Glu Thr Trp Thr Met Lys Asn Val Tyr Asn Ser Trp Thr Tyr Asn Val Gln Tyr Trp Lys Asn Gly Thr Asp Glu Ly Phe Gln Ile Thr Pro Gln Tyr Asp Phe Glu Val Leu Arg Asn Leu Glu\Pro Trp Thr Thr Tyr Cys Val Gln Val Arg Gly Phe Leu Pro Asp Arg Asn Lys Ala Gly Glu Trp Ser Glu Pro Val Cys Glu Gln Thr Thr His Asp Glu Thr Val Pro Ser Trp Met Val Ala Val Ile Leu Met Ala Ser Val Phe Met Val Cys Leu Ala Leu Leu Gly Cys Phe Ser Leu Leu Trp Cys Val Tyr Lys Lys Thr Lys Tyr Ala Phe Ser Pro Arg Asn Ser Leu Pro Gln\His Leu Lys Glu Phe Leu Gly His Pro His His Asn Thr Leu Leu Phe Rhe Ser Phe Pro Leu Ser Asp Glu Asn Asp Val Phe Asp Lys Leu Ser Vall Ile Ala Glu Asp Ser Glu Ser Gly Lys Gln Asn Pro Gly Asp Ser Cys\Ser Leu Gly Thr Pro Pro Gly Gln Gly Pro Gln Ser

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 CFR 1.8:
`	1.825. Applicant's attention is directed to these regulations, published at 114 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on
	paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been
	submitted as required by 37 CFR 1.821(e).
X	A B constant the Monte of the M
تک	4. A copy of the "Sequence Listing" in computer readable form has been submitte.
	However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of marked-up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has bee
	found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as requirely. 37 CFR 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer
	readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
<u></u>	
	7. Other:————————————————————————————————————
, .	
Appli	cant must provide:
K TI	
中	An initial or substitute computer readable form (CRF) copy of the "Sequence
<u>_</u>	Listing"
四	An initial or substitute paper copy of the "Sequence Listing", as well as an
1 -	amendment directing its entry into the specification
^	

and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

A statement that the content of the paper and computer readable copies are the s

For questions regarding compliance with these requirements, please conta

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.